Codon-specific KRAS mutations are predictive of an overall survival (OS) benefit for metastatic colorectal cancer (mCRC) patients treated with trifluridine-tipiracil (FTD/TPI; Lonsurf), according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback